SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
03 06 2020
Historique:
received: 22 04 2020
accepted: 28 05 2020
entrez: 5 6 2020
pubmed: 5 6 2020
medline: 17 6 2020
Statut: epublish

Résumé

COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.

Identifiants

pubmed: 32493510
doi: 10.1186/s12967-020-02392-y
pii: 10.1186/s12967-020-02392-y
pmc: PMC7268185
doi:

Substances chimiques

Antibodies, Viral 0
COVID-19 Vaccines 0
Spike Glycoprotein, Coronavirus 0
Viral Vaccines 0
spike protein, SARS-CoV-2 0

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

222

Références

Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8
pubmed: 26216974
Virol Sin. 2018 Apr;33(2):201-204
pubmed: 29541941
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14
pubmed: 25073113
Nat Med. 2004 Aug;10(8):871-5
pubmed: 15247913
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
PLoS One. 2012;7(4):e35421
pubmed: 22536382
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9
pubmed: 15210961
Virol J. 2014 May 06;11:82
pubmed: 24885320

Auteurs

Giovanni Salvatori (G)

Takis s.r.l, Via di Castel Romano 100, 00128, Rome, Italy.

Laura Luberto (L)

Takis s.r.l, Via di Castel Romano 100, 00128, Rome, Italy.

Mariano Maffei (M)

Evvivax s.r.l, Via di Castel Romano, 100, 00128, Rome, Italy.

Luigi Aurisicchio (L)

Takis s.r.l, Via di Castel Romano 100, 00128, Rome, Italy.
Evvivax s.r.l, Via di Castel Romano, 100, 00128, Rome, Italy.

Giuseppe Roscilli (G)

Takis s.r.l, Via di Castel Romano 100, 00128, Rome, Italy.
Evvivax s.r.l, Via di Castel Romano, 100, 00128, Rome, Italy.

Fabio Palombo (F)

Takis s.r.l, Via di Castel Romano 100, 00128, Rome, Italy.

Emanuele Marra (E)

Takis s.r.l, Via di Castel Romano 100, 00128, Rome, Italy. marra@takisbiotech.it.
Evvivax s.r.l, Via di Castel Romano, 100, 00128, Rome, Italy. marra@takisbiotech.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH